Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure
- 22 July 2011
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 21 (3) , 233-240
Abstract
Objective: There is little evidence on comparative effectiveness of individual angiotensin receptor blockers (ARBs) in patients with chronic heart failure (CHF). This study compared four ARBs in reducing risk of mortality in clinical practice.Methods: A retrospective analysis was conducted on a national sample of patients diagnosed with CHF from 1 October 1996 to 30 September 2002 identified from Veterans Affairs electronic medical records, with supplemental clinical data obtained from chart review. After excluding patients with exposure to ARBs within the previous 6 months, four treatment groups were defined based on initial use of candesartan, valsartan, losartan, and irbesartan between the index date (1 October 2000) and the study end date (30 September 2002). Time to death was measured concurrently during that period. A marginal structural model controlled for sociodemographic factors, comorbidities, comedications, disease severity (left ventricular ejection fraction), and potential time‐varying confounding affected by previous treatment (hospitalization). Propensity scores derived from a multinomial logistic regression were used as inverse probability of treatment weights in a generalized estimating equation to estimate causal effects.Results: Among the 1536 patients identified on ARB therapy, irbesartan was most frequently used (55.21%), followed by losartan (21.74%), candesartan (15.23%), and valsartan (7.81%). When compared with losartan, after adjusting for time‐varying hospitalization in marginal structural model, candesartan (OR = 0.79, 95%CI = 0.42–1.50), irbesartan (OR = 1.17, 95%CI = 0.72–1.90), and valsartan (OR = 0.98, 95%CI = 0.45–2.14) were found to have similar effectiveness in reducing mortality in CHF patients.Conclusion: Effectiveness of ARBs in reducing mortality is similar in patients with CHF in everyday clinical practice. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
Funding Information
- Agency for Healthcare Research and Quality (1R03HS0169-01A1)
- Department of Veterans Affairs, Health Services Research and Development Service (IIR02-083)
- Houston VA HSR&D Center of Excellence (HFP90-020)
This publication has 23 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2009 UpdateCirculation, 2009
- Traditional versus marginal structural models to estimate the effectiveness of β‐blocker use on mortality after myocardial infarctionPharmacoepidemiology and Drug Safety, 2008
- Constructing Inverse Probability Weights for Marginal Structural ModelsAmerican Journal of Epidemiology, 2008
- Comparative Effectiveness of Beta-Adrenergic Antagonists (Atenolol, Metoprolol Tartrate, Carvedilol) on the Risk of Rehospitalization in Adults With Heart FailureThe American Journal of Cardiology, 2007
- Do ACE Inhibitors/Angiotensin II Type 1 Receptor Antagonists Reduce Hospitalisations in Older Patients with Heart Failure?Drugs & Aging, 2007
- Racial variations in quality of care and outcomes in an ambulatory heart failure cohortAmerican Heart Journal, 2006
- Efficacy and Duration of Action of the Four Selective Angiotensin II Subtype 1 Receptor Blockers, Losartan, Candesartan, Valsartan and Telmisartan, in Patients with Essential Hypertension Determined by Home Blood Pressure MeasurementsClinical and Experimental Hypertension, 2005
- Use of 24-Hour Ambulatory Blood Pressure Monitoring to Assess Antihypertensive EfficacyAmerican Journal of Cardiovascular Drugs, 2005
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunctionProgress in Cardiovascular Diseases, 1999